NZ594122A - 2-Phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide derivatives - Google Patents

2-Phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide derivatives

Info

Publication number
NZ594122A
NZ594122A NZ594122A NZ59412209A NZ594122A NZ 594122 A NZ594122 A NZ 594122A NZ 594122 A NZ594122 A NZ 594122A NZ 59412209 A NZ59412209 A NZ 59412209A NZ 594122 A NZ594122 A NZ 594122A
Authority
NZ
New Zealand
Prior art keywords
phenyl
pyrrolidin
ylmethyl
thiazolo
pyridin
Prior art date
Application number
NZ594122A
Other languages
English (en)
Inventor
Christopher Oalmann
Jeremy S Disch
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ594122(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of NZ594122A publication Critical patent/NZ594122A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ594122A 2008-12-19 2009-12-18 2-Phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide derivatives NZ594122A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20315608P 2008-12-19 2008-12-19
PCT/US2009/068865 WO2010071853A1 (en) 2008-12-19 2009-12-18 Thiazolopyridine sirtuin modulating compounds

Publications (1)

Publication Number Publication Date
NZ594122A true NZ594122A (en) 2013-03-28

Family

ID=42269132

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ594122A NZ594122A (en) 2008-12-19 2009-12-18 2-Phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide derivatives

Country Status (22)

Country Link
US (2) US8343997B2 (cg-RX-API-DMAC7.html)
EP (1) EP2376502B1 (cg-RX-API-DMAC7.html)
JP (1) JP5628828B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110110194A (cg-RX-API-DMAC7.html)
CN (1) CN102388054B (cg-RX-API-DMAC7.html)
BR (1) BRPI0922435A2 (cg-RX-API-DMAC7.html)
CA (1) CA2747715A1 (cg-RX-API-DMAC7.html)
CO (1) CO6400181A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110353A (cg-RX-API-DMAC7.html)
DO (1) DOP2011000188A (cg-RX-API-DMAC7.html)
EA (1) EA021424B1 (cg-RX-API-DMAC7.html)
ES (1) ES2544258T3 (cg-RX-API-DMAC7.html)
IL (1) IL213217A0 (cg-RX-API-DMAC7.html)
MA (1) MA32909B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011006555A (cg-RX-API-DMAC7.html)
MY (1) MY160006A (cg-RX-API-DMAC7.html)
NZ (1) NZ594122A (cg-RX-API-DMAC7.html)
PE (1) PE20120057A1 (cg-RX-API-DMAC7.html)
SG (1) SG171835A1 (cg-RX-API-DMAC7.html)
UA (1) UA104447C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010071853A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201104060B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
SG190603A1 (en) 2008-05-01 2013-06-28 Sirtris Pharmaceuticals Inc Quinolines and related analogs as sirtuin modulators
MX2011000079A (es) * 2008-07-03 2011-03-02 Sirtris Pharmaceuticals Inc Bencimidazoles y analogos relacionados como moduladores de sirtuin.
MX2011003373A (es) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Quinazolinona, quinolona y analogos relacionados como moduladores de sirtuina.
MX2012004995A (es) 2009-10-29 2012-10-03 Sirtris Pharmaceuticals Inc Piridinas biciclicas y analogos como moduladores de sirtuina.
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
BR112014028017A2 (pt) 2012-05-08 2017-06-27 Lycera Corp composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US20150166528A1 (en) 2012-06-14 2015-06-18 Basf Se Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests
WO2016081692A2 (en) * 2014-11-19 2016-05-26 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators
KR20160006215A (ko) 2013-05-13 2016-01-18 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 가교 우레아 유사체
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
US10316054B2 (en) 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
JP6559713B2 (ja) 2014-06-06 2019-08-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ニコチンアミドリボシド類似体ならびにその医薬組成物および使用
EP3256450B1 (en) 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US9782859B2 (en) * 2015-07-16 2017-10-10 Siemens Energy, Inc. Slag free flux for additive manufacturing
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用
JP2018531957A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としての置換二環式ピラゾール化合物及びその使用
EP3368539B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Substituted indazole compounds as ror gamma t inhibitors and uses thereof
CA3015345A1 (en) 2016-02-23 2017-08-31 Indiana University Research & Technology Corporation Combination therapies for treatment of spinal muscular atrophy
WO2020247608A1 (en) * 2019-06-04 2020-12-10 The Regents Of The University Of California Small molecule inhibitors of a protein complex

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164603A (en) 1965-01-05 xnhcox
DE1108698B (de) 1959-09-03 1961-06-15 Hoechst Ag Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen
FR1439129A (fr) 1965-04-02 1966-05-20 Chimetron Nouveaux sulfonylbenzimidazoles
FR1476529A (fr) 1965-04-24 1967-04-14 Chimetron Sarl Nouveaux dérivés benzimidazole-sulfoniques et sulfamides correspondants
US3503929A (en) 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
US3517007A (en) 1968-04-05 1970-06-23 American Home Prod 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds
US3928228A (en) 1969-04-28 1975-12-23 Sterling Drug Inc 4,4{40 -Stilbenebis-pyridooxazoles and related optical brighteners and polymeric compositions brightened thereby
US3712888A (en) 1970-12-14 1973-01-23 American Cyanamid Co Bis-pyridoxazole-stilbene derivatives for optical brightening
CA1006165A (en) 1971-04-06 1977-03-01 Eastman Kodak Company Ballasted color photographic couplers
AR208500A1 (es) 1972-06-14 1977-02-15 Merck & Co Inc Procedimiento para la preparacion de derivados de oxazolo(4,5-b)-piridinas
US4038396A (en) 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
PL96241B1 (pl) 1975-06-30 1977-12-31 Sposob wytwarzania 2-/2-podstawionych-4-tiazolilo/-benzimidazoli
JPS6040016B2 (ja) 1977-08-31 1985-09-09 コニカ株式会社 マゼンタ色素画像の形成方法
US4471040A (en) 1980-09-10 1984-09-11 Canon Kabushiki Kaisha Electrophotographic disazo photosensitive member
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
DE3807084A1 (de) 1988-03-04 1989-09-14 Knoll Ag Neue benzimidazo(1,2-c)chinazoline, ihre herstellung und verwendung
JPH04190232A (ja) 1990-11-26 1992-07-08 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
JPH06247969A (ja) 1992-12-28 1994-09-06 Takeda Chem Ind Ltd 縮合複素環化合物及びそれを含む農園芸用殺虫剤
ES2172585T3 (es) 1994-05-31 2002-10-01 Mitsui Chemicals Inc Derivado de benzoimidazol.
AUPN449295A0 (en) 1995-07-28 1995-08-24 Inner And Eastern Health Care Network, The Radioprotectors
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5808087A (en) 1995-11-29 1998-09-15 Mitsui Chemicals, Inc. Sulfonium salts of pyrrolylbenzimidazoles
JP2002509858A (ja) 1997-12-31 2002-04-02 ルトガーズ，ザ ステイト ユニバーシティ オブ ニュージャージー 複素環式トポイソメラーゼ毒化合物
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
AU778393B2 (en) 1999-05-12 2004-12-02 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
SK286857B6 (sk) 1999-06-23 2009-06-05 Sanofi-Aventis Deutschland Gmbh Substituované benzimidazoly, spôsob ich prípravy, ich použitie a liečivo, ktoré ich obsahuje
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
AU2001259707A1 (en) 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP2002161084A (ja) 2000-11-28 2002-06-04 Sumitomo Pharmaceut Co Ltd 複素環誘導体
US20040010033A1 (en) 2001-02-20 2004-01-15 Pfizer Inc. Non-peptide GnRH agents, methods and intermediates for their preparation
WO2002066454A1 (fr) 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
CZ20032615A3 (en) 2001-03-28 2004-03-17 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
NZ530580A (en) 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU2002368274A1 (en) 2001-09-13 2004-06-03 Genesoft, Inc. Methods of treating infection by drug resistant bacteria
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
AU2002349477A1 (en) 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
EP1452530A4 (en) 2001-12-03 2005-11-30 Japan Tobacco Inc AZOL CONNECTION AND THEIR MEDICAL USE
MXPA04007697A (es) 2002-02-06 2004-11-10 Vertex Pharma Compuestos de heteroarilo utiles como inhibidores de gsk-3.
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
CA2479069A1 (en) 2002-03-18 2003-09-25 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
NZ535603A (en) 2002-03-20 2007-10-26 Metabolex Inc Substituted phenylacetic acids
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP4224979B2 (ja) 2002-04-09 2009-02-18 大正製薬株式会社 インターロイキン１２抑制剤
JP4239463B2 (ja) 2002-04-09 2009-03-18 大正製薬株式会社 ３−トリフルオロメチルアニリド誘導体
MXPA04010172A (es) 2002-04-18 2005-02-03 Schering Corp 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3).
JP2003313176A (ja) 2002-04-24 2003-11-06 Sankyo Co Ltd アミノアゾール誘導体
WO2004007455A1 (de) 2002-07-12 2004-01-22 Aventis Pharma Deutschland Gmbh Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP2004075614A (ja) 2002-08-20 2004-03-11 Sankyo Co Ltd クロメン誘導体を含有する医薬
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
JP2006515274A (ja) 2002-10-08 2006-05-25 マサチューセッツ・インスティテュート・オブ・テクノロジー コレステロール輸送の調節のための化合物
WO2004033434A1 (en) 2002-10-09 2004-04-22 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
AU2003299378A1 (en) 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2004039318A2 (en) 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004050833A2 (en) 2002-11-27 2004-06-17 University Of North Carolina At Chapel Hill Glyceraldehyde 3-phosphate dehydrogenase-s(gapds), a glycolytic enzyme expressed only in male germ cells,is a target for male contraception
DE10300398A1 (de) 2003-01-09 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel
WO2004069160A2 (en) 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
AU2004212490B2 (en) 2003-02-10 2008-05-15 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
CN103265477B (zh) 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
BRPI0408251A (pt) 2003-03-11 2006-03-01 Pfizer Prod Inc compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
US7459454B2 (en) 2003-03-21 2008-12-02 Smithkline Beecham Corporation Aminopyrazine derivatives and compositions
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB2405793A (en) 2003-09-12 2005-03-16 4 Aza Bioscience Nv Pteridine derivatives for treating TNF-alpha related disorders
AU2004271721A1 (en) 2003-09-12 2005-03-24 4 Aza Bioscience Nv Pteridine derivatives for the treatment of septic shock and TNF-alpha-related diseases.
AU2004274154A1 (en) 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
JP4795634B2 (ja) 2003-10-31 2011-10-19 出光興産株式会社 有機薄膜トランジスタ
JP2005162855A (ja) 2003-12-02 2005-06-23 Konica Minolta Holdings Inc 着色組成物、インクジェット記録用インク、カラートナー、光記録媒体、感熱転写記録材料用インクシート、カラーフィルター、及び該インクジェット記録用インクを用いたインクジェット記録方法
JP4890270B2 (ja) 2004-02-11 2012-03-07 バジリア ファルマスーチカ アーゲー 置換ベンゾイミダゾール及びアポトーシスを誘導するためのこれらの使用
WO2005100342A1 (en) 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
ME02799B (me) 2004-06-24 2018-01-20 Vertex Pharma Modulatori ATP-vezujućih kasetnih transportera
MX2007001727A (es) 2004-08-13 2007-04-20 Genentech Inc Compuestos a base de 2-amido-tiazol que exhiben actividad inhibidora de enzima que utiliza atp y composiciones y usos de los mismos.
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
NZ555419A (en) 2004-11-03 2009-07-31 Curis Inc Mediators of the hedgehog gene signaling pathways, compositions and uses related thereto
TW200628159A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
AU2006218405A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline derivatives as sirtuin modulators
EP1853610A1 (en) 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CN101277965A (zh) * 2005-08-04 2008-10-01 西特里斯药业公司 作为SIRTUIN调节化合物的咪唑并[2,1-b]噻唑衍生物
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
AU2006278397B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
KR101354265B1 (ko) 2006-07-14 2014-01-22 토요잉크Sc홀딩스주식회사 폴리에스테르 분산제와 그의 제조방법, 및 그것을 이용한 안료 조성물
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
EA201070551A1 (ru) 2007-11-01 2010-12-30 Сертрис Фармасьютикалз, Инк. Сиртуинмодулирующие соединения
WO2009061453A1 (en) * 2007-11-08 2009-05-14 Sirtris Pharmaceuticals, Inc. Solubilized thiazolopyridines
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
US20120108585A1 (en) 2008-08-12 2012-05-03 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators

Also Published As

Publication number Publication date
EA201170847A1 (ru) 2011-12-30
MA32909B1 (fr) 2011-12-01
CA2747715A1 (en) 2010-06-24
BRPI0922435A2 (pt) 2018-09-11
ZA201104060B (en) 2012-02-29
JP2012512907A (ja) 2012-06-07
UA104447C2 (uk) 2014-02-10
DOP2011000188A (es) 2011-07-31
CN102388054A (zh) 2012-03-21
US8343997B2 (en) 2013-01-01
US20130085155A1 (en) 2013-04-04
ES2544258T3 (es) 2015-08-28
EP2376502B1 (en) 2015-06-17
CR20110353A (es) 2011-10-27
PE20120057A1 (es) 2012-02-24
MY160006A (en) 2017-02-15
US8492401B2 (en) 2013-07-23
IL213217A0 (en) 2011-07-31
KR20110110194A (ko) 2011-10-06
EP2376502A1 (en) 2011-10-19
EP2376502A4 (en) 2012-07-18
WO2010071853A1 (en) 2010-06-24
SG171835A1 (en) 2011-07-28
CO6400181A2 (es) 2012-03-15
EA021424B1 (ru) 2015-06-30
JP5628828B2 (ja) 2014-11-19
CN102388054B (zh) 2015-03-04
MX2011006555A (es) 2011-08-03
US20110306609A1 (en) 2011-12-15
AU2009327373A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
NZ594122A (en) 2-Phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide derivatives
JP2010530432A5 (cg-RX-API-DMAC7.html)
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
JP6021805B2 (ja) 腫瘍治療剤
NZ578876A (en) 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
JP2011513305A5 (cg-RX-API-DMAC7.html)
MX2010009922A (es) Activadores de piridazinona glucocinasa.
JP2009526830A5 (cg-RX-API-DMAC7.html)
MX2008016423A (es) Arilamidas sustituidas con tetrazol.
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
TN2012000608A1 (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
JP2005518357A5 (cg-RX-API-DMAC7.html)
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
EP3468604B1 (en) Pharmaceutical combinations for treating cancer
NZ601077A (en) Use of an adrenal hormone-modifying agent
JP2012512863A5 (cg-RX-API-DMAC7.html)
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
Wurz et al. Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1, 3, 5-triazine sulfonamide scaffold
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
WO2008136444A1 (ja) 縮合複素環誘導体
TW200643013A (en) Pyrazoles
WO2009095923A3 (en) Corroles for neuroprotection and neurorescue

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 DEC 2016 BY THOMSON REUTERS

Effective date: 20130920

LAPS Patent lapsed